<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865917</url>
  </required_header>
  <id_info>
    <org_study_id>CCB-CRC-07-02</org_study_id>
    <nct_id>NCT00865917</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Selective I(f)-Channel Blockade</brief_title>
  <official_title>Einfluss Selektiver I(f)-Blockade Auf Orthostase-Toleranz Und Sympathikusaktivität Bei Gesunden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares three treatment modalities in a human model of Postural orthostatic
      tachycardia syndrome (POTS): beta-blockers, I(f)-blockers, and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated heart rate may lead to cardiac disease in the long-term. Therefore, drugs lowering
      heart rate are useful. Beta-blockers are an established treatment modality. They not only
      lower heart rate but also contractility, which might be undesirable in certain tachycardic
      disorders.

      Postural orthostatic tachycardia syndrome (POTS) patients complain about dizziness, weakness,
      headache, lightheadedness, fatigue, nausea, and presyncope. In some patients there is
      elevated heart rate even during supine rest. In POTS patients it is preferable to lower heart
      rate without reducing cardiac contractility which can be achieved by using so-called
      I(f)-blockers. Thus, they might be superior to beta-blockers in POTS.

      In our study, we artificially generate POTS in healthy male subjects for about 48 hours. We
      want to compare the cardiovascular effects and orthostatic tolerance of the following
      treatments: beta-blocker, I(f)-blocker, and placebo.

      Moreover, we will quantify changes in cardiovascular autonomic regulation brought about by
      I(f)-blockade versus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-study 'Orthostatic tolerance': Change in heart rate after 20 mins of passive orthostasis. Sub-study 'Sympathetic system': arterial pressure related heart rate</measure>
    <time_frame>12-18 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>'Orthostatic tolerance': Hemodynamics during head-up tilt. Time to presyncope.</measure>
    <time_frame>12-18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>'Sympathetic system': Muscle sympathetic nerve activity (MSNA).</measure>
    <time_frame>12-18 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beta-blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I(f)-blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta-blocker (Metoprolol)</intervention_name>
    <description>Metoprolol 95 mg once per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I(f)-blocker (ivabradine)</intervention_name>
    <description>ivabradine 7.5 mg once per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching appearance</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male

          -  age 18-40 years

          -  BMI: 18-30 kg/m²

          -  arterial blood pressure &lt;=160/100 mm Hg

          -  co-operativity

          -  voluntariness

        Exclusion Criteria:

          -  conditions in which treatment might be ineffective or insecure

          -  co-medication within the last 4 weeks

          -  participation in another clinical trial within the last 4 weeks

          -  unability to understand the study's aim

          -  drug or alcohol abuse

          -  secondary hypertension

          -  creatinine &gt; 130 μM (1.47 mg/dl)

          -  GOT/GPT &gt; 2 times normal

          -  GGT &gt; 3 times normal

          -  contraindications against reboxetine, beta-blocker, ivabradine

          -  asthma, psoriasis

          -  diabetes

          -  heart failure (NYHA III or IV)

          -  coronary artery disease

          -  peripheral occlusive disease

          -  cerebrovascular disease

          -  ventricular extrasystoles (Lown III-V)

          -  atrial fibrillation

          -  resting heart rate &lt;60/min

          -  neurologic/psychiatric disorder

          -  pulmonary hypertension

          -  dysthyroid metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Jordan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidrun Mehling, MD</last_name>
    <phone>+49(0)30</phone>
    <phone_ext>94171296</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Tank, MD</last_name>
    <phone>+49(0)511</phone>
    <phone_ext>532 2723</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Franz-Volhard Centrum für Klinische Forschung</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidrun Mehling, MD</last_name>
      <phone>+49(0)30</phone>
      <phone_ext>94171296</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Tank, MD</last_name>
      <phone>+49(0)30</phone>
      <phone_ext>5322723</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Karsten Heusser, MD</last_name>
      <phone>+49(0)30</phone>
      <phone_ext>5322723</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>March 18, 2009</last_update_submitted>
  <last_update_submitted_qc>March 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Heidrum Mehling, Dr. med.</name_title>
    <organization>Franz-Volhard-Centrum für Klinische Forschung</organization>
  </responsible_party>
  <keyword>POTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

